Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Allarity Therapeutics, Inc.ALLR · Entity 7594 | CEO | January 28, 2026 | May 14, 2026 |
| Valion Bio, Inc.VBIO · Entity 8459 | Director | August 27, 2026 | September 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Allarity Therapeutics, Inc.
Report date January 28, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 596,734 |
Reported balance
After 2026-01-28 transaction · row 1
1 source rowRow 1 · 2026-01-28 · Grant · Acquired 200,000 · Balance 596,734 F1: The restricted stock units, or RSUs, granted on January 28, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, will vest in equal one-third installments on the first, second, and third anniversary of the grant, subject to the Reporting Person's continued relationship with the Issuer through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units, or RSUs, granted on January 28, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, will vest in equal one-third installments on the first, second, and third anniversary of the grant, subject to the Reporting Person's continued relationship with the Issuer through each such date.
Valion Bio, Inc.
Report date August 27, 2026 · Filed September 17, 2026
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 28, 2026 Filed May 14, 2026 15:48 UTC | Allarity Therapeutics, Inc. ALLR · Entity 7594 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-056373 · ownership.xml · nonDerivative · entry 1 Jensen Thomas · CIK 0001888277 · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 596,734 F1 · shares: The restricted stock units, or RSUs, granted on January 28, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, will vest in equal one-third installments on the first, second, and third anniversary of the grant, subject to the Reporting Person's continued relationship with the Issuer through each such date. Read SEC document |
| January 22, 2025 Filed Jan 24, 2025 21:16 UTC | Allarity Therapeutics, Inc. ALLR · Entity 7594 | GrantCommon Stock | 396,734 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-001801 · rdgdoc.xml · nonDerivative · entry 1 Jensen Thomas · CIK 0001888277 · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 396,734 F1 · shares: The restricted stock units, or RSUs, granted on January 22, 2025 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, will vest in equal one-third installments on the first, second, and third anniversary of the grant, subject to the Reporting Person's continued relationship with the Issuer through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.